ROMO vs DEN. Romosozumab was superior to denosumab (ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me